CytoReason: Valuation, Funding & Investors
CytoReason is a computational biology company that builds predictive, mechanistic models of human tissues and disease using single-cell and multi-omics data. Its platform generates in-silico patient models and disease simulations to help biopharma teams prioritize targets, predict drug responses, and accelerate preclinical and translational research. CytoReason partners with pharmaceutical and biotechnology organizations to apply its modeling solutions across therapeutic discovery and development workflows.
Leadership & Board
- Current Number of Employees
- 106
- Current LinkedIn Followers
- 13,760
Latest Estimated Valuation
- Total Amount Raised
- $80M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $80M
- Latest Funding Round
- Series B
Company Momentum Positive
CytoReason LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
CytoReason had 106 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
CytoReason had 13,760 followers as of October 26, 2026. The number of followers increased by 38 (0.28%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 17, 2024 | Series B | $80.00M | ― |
Similar Companies
A snapshot of private companies similar to CytoReason, helping you discover and navigate related company profiles.
Related News and Analysis
